PTSDに対する星状神経節ブロックと長期暴露の組み合わせ
PTSDに対する星状神経節ブロックと長期曝露の組み合わせ:ランダム化臨床試験
The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of military service members or retirees with PTSD. The main questions it aims to answer are: (1) Does the addition of an SGB improve treatment outcomes associated with Massed PE and (2) Do differences in psychophysiological arousal during the exposure portion of treatment help explain treatment outcomes for PTSD. Participants will receive ten 90-minute session of Massed PE. Between the first and second Massed PE sessions, half of the participants will receive a SGB, and half will receive a sham SGB.
調査の概要
詳細な説明
Massed PE will be conducted by master-level or doctoral-level therapists. Participants will meet with their providers for individual, 90-minute sessions. They will then be asked to complete out-of-session treatment assignments throughout the rest of the day. Between the individual therapy session and out-of-session treatment assignments, participants will engage in approximately four to six hours of treatment per day, Monday through Friday, for two weeks. Each participant will also be offered three booster sessions at 1-, 3-, and 7-weeks posttreatment.
The stellate ganglion block injection or the sham SGB will be administered between the first and second massed PE session by qualified medical personnel as per standard operating procedure for the placement of a stellate ganglion block. A research nurse will be in attendance during the procedure and for an hour recovery period following the block administration.
Assessments will be administered at pretreatment, during treatment, at posttreatment, and at 1-, 3-, and 6-months following the completion of PE. The primary outcome assessment will be 1-month following the completion of PE. Following this assessment, participants randomized to the sham SGB arm of the study will be offered an SGB with ropivacaine.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Amanda Flores
- 電話番号:210-562-6726
- メール:floresa13@uthscsa.edu
研究場所
-
-
Texas
-
Fort Hood、Texas、アメリカ、76544
- 募集
- Carl R. Darnall Army Medical Center
-
コンタクト:
- Paul Fowler
- 電話番号:726-225-5520
- メール:fowlerp@uthscsa.edu
-
主任研究者:
- Caleb Dickinson, DO
-
Fort Sam Houston、Texas、アメリカ、78234
- 募集
- Brook Army Medical Center (BAMC)
-
コンタクト:
- Wilson B Pfeiffer, DO
- 電話番号:210-916-8256
- メール:wilson.b.pfeiffer.mil@health.mil
-
主任研究者:
- Wilson B Pfeiffer, Do
-
San Antonio、Texas、アメリカ、78229
- 募集
- University of Texas Health Science Center at San Antonio
-
コンタクト:
- Amanda Flores
- 電話番号:210-562-6726
- メール:floresa13@uthscsa.edu
-
主任研究者:
- Alan Peterson, PhD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Active duty and retired military service members ages 18-65 years
- PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale
- Able to speak and read English (due to standardization of outcome measures)
- Defense Enrollment Eligibility Reporting System (DEERS)-eligible to receive care at a military treatment facility (MTF) where the stellate ganglion block will be placed.
Exclusion Criteria:
- Current suicidal ideation severe enough to warrant immediate attention (as determined by the Depressive Symptoms Index - Suicidality Subscale and the Self-Injurious Thoughts and Behaviors Interview short form) and corroborated by a clinical risk assessment by a credentialed provider.
- Current manic episode or psychotic symptoms requiring immediate stabilization or hospitalization (as determined by clinical judgment)
- Symptoms of moderate to severe substance use (to include alcohol) warranting immediate intervention based on clinical judgment.
- Other psychiatric disorders severe enough to warrant designation as the primary disorder as determined by clinician judgment
- Pregnancy or breastfeeding
- Current anticoagulant use
- History of bleeding disorder
- Infection or mass at injection site
- Myocardial infarction within 6 months of procedure
- Pathologic bradycardia or irregularities of heart rate or rhythm
- Symptomatic hypotension
- Phrenic or laryngeal nerve palsy
- History of glaucoma
- Uncontrolled seizure disorder
- History of allergy to local anesthetics
- Current use of Class III antiarrhythmics
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Stellate Ganglion Block
One time administration of a stellate ganglion block |
6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
他の名前:
|
|
プラセボコンパレーター:Sham SGB
One time administration |
6.5cc of Normal Saline one time into the stellate ganglion. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline in Clinician-Administered PTSD Scale-DSM 5 (CAPS-5)
時間枠:Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 30-item structured interview used to assess change symptoms of PTSD. Questions target the onset and duration of symptoms, subjective distress, impact on social and occupational functioning. Total severity scores range from 0 to 80 with higher score indicative of greater PTSD severity. The measure can also be used to confirm the presence of a PTSD diagnosis. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Change from baseline in Posttraumatic Stress Disorder Checklist -DSM 5 (PCL-5)
時間枠:Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 20-item self-report measure that assesses the presence and change in severity of PTSD symptoms using the Diagnostic and Statistical Manual of mental disorders (DSM-5). Total severity scores range from 0 to 80 with higher score indictive of greater PTSD severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient Health Questionnaire-9 items (PHQ-9)
時間枠:Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 9-item self-report measure that assesses the presence and change in severity of depressive symptoms. Total scores range from 0 to 27 with higher scores reflective of greater severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
General Anxiety Disorder Screener - 7 Items (GAD-7)
時間枠:Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 9-item self-report measure that assesses the presence and change in severity of general anxiety symptoms. Total scores range from 0 to 21 with higher scores reflective of greater severity. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Posttraumatic Cognitions Inventory (PTCI)
時間枠:Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
A 36-item self-report measure that assesses change in self-blame, negative cognitions about self, and negative cognitions about the world following trauma exposure. Total scores range from 33 to 231 with higher scores reflective of more problematic cognitions. |
Baseline and at 1-month, 3-month, and 6-month follow-up assessments
|
|
Psychophysiological arousal - Galvanic Skin Response
時間枠:Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring galvanic skin response |
Two weeks
|
|
Psychophysiological arousal - Skin Temperature
時間枠:Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring skin temperature |
Two weeks
|
|
Psychophysiological arousal - Heart Rate
時間枠:Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring heart rate |
Two weeks
|
|
Psychophysiological arousal - Interbeat Interval
時間枠:Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring interbeat interval |
Two weeks
|
|
Psychophysiological arousal - Three-Dimensional Accelerometer Movement
時間枠:Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring three-dimensional accelerometer movement |
Two weeks
|
|
Psychophysiological arousal - Electrodermal Activity
時間枠:Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring electrodermal activity |
Two weeks
|
|
Psychophysiological arousal - Photoplethysmography
時間枠:Two weeks
|
Change in Psychophysiological data collected from a smart watch measuring photoplethysmography |
Two weeks
|
協力者と研究者
捜査官
- 主任研究者:Alan Peterson, PhD、The University of Texas Health Science Center at San Antonio
出版物と役立つリンク
一般刊行物
- Lipov EG, Joshi JR, Lipov S, Sanders SE, Siroko MK. Cervical sympathetic blockade in a patient with post-traumatic stress disorder: a case report. Ann Clin Psychiatry. 2008 Oct-Dec;20(4):227-8. doi: 10.1080/10401230802435518. No abstract available.
- Lynch JH, Mulvaney SW, Kim EH, de Leeuw JB, Schroeder MJ, Kane SF. Effect of Stellate Ganglion Block on Specific Symptom Clusters for Treatment of Post-Traumatic Stress Disorder. Mil Med. 2016 Sep;181(9):1135-41. doi: 10.7205/MILMED-D-15-00518.
- Mulvaney SW, Lynch JH, Hickey MJ, Rahman-Rawlins T, Schroeder M, Kane S, Lipov E. Stellate ganglion block used to treat symptoms associated with combat-related post-traumatic stress disorder: a case series of 166 patients. Mil Med. 2014 Oct;179(10):1133-40. doi: 10.7205/MILMED-D-14-00151.
- Hanling SR, Hickey A, Lesnik I, Hackworth RJ, Stedje-Larsen E, Drastal CA, McLay RN. Stellate Ganglion Block for the Treatment of Posttraumatic Stress Disorder: A Randomized, Double-Blind, Controlled Trial. Reg Anesth Pain Med. 2016 Jul-Aug;41(4):494-500. doi: 10.1097/AAP.0000000000000402.
- Odosso RJ, Petta L. The Efficacy of the Stellate Ganglion Block as a Treatment Modality for Posttraumatic Stress Disorder Among Active Duty Combat Veterans: A Pilot Program Evaluation. Mil Med. 2021 Jul 1;186(7-8):e796-e803. doi: 10.1093/milmed/usaa246.
- Peterson AL, Blount TH, Foa EB, Brown LA, McLean CP, Mintz J, Schobitz RP, DeBeer BR, Mignogna J, Fina BA, Evans WR, Synett S, Hall-Clark BN, Rentz TO, Schrader C, Yarvis JS, Dondanville KA, Hansen H, Jacoby VM, Lara-Ruiz J, Straud CL, Hale WJ, Shah D, Koch LM, Gerwell KM, Young-McCaughan S, Litz BT, Meyer EC, Blankenship AE, Williamson DE, Roache JD, Javors MA, Sharrieff AM, Niles BL, Keane TM; Consortium to Alleviate PTSD. Massed vs Intensive Outpatient Prolonged Exposure for Combat-Related Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2023 Jan 3;6(1):e2249422. doi: 10.1001/jamanetworkopen.2022.49422.
- Foa EB, McLean CP, Zang Y, Rosenfield D, Yadin E, Yarvis JS, Mintz J, Young-McCaughan S, Borah EV, Dondanville KA, Fina BA, Hall-Clark BN, Lichner T, Litz BT, Roache J, Wright EC, Peterson AL; STRONG STAR Consortium. Effect of Prolonged Exposure Therapy Delivered Over 2 Weeks vs 8 Weeks vs Present-Centered Therapy on PTSD Symptom Severity in Military Personnel: A Randomized Clinical Trial. JAMA. 2018 Jan 23;319(4):354-364. doi: 10.1001/jama.2017.21242.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HSC20230087H
- W81XWH2220055 (その他の助成金/資金番号:Department of Defense)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。